| Biomarker ID | 1036 |
| PMID | 23308129 |
| Year | 2013 |
| Biomarker | BMI1 |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa: (Normal: 0.81 ± 0.07; PCa stage 2: 1.8 ± 0.08) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: PRC2 complex long-term gene silencing through modification of histone tails, Myc active pathway, Senescence and autophagy, T cell receptor regulation of apoptosis |
| Experiment | Normal Vs PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 70 pair- matched specimens of normal and CaP representing all tumor stages were selected for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p< 0.05 |
| Method Used | Immunohistochemistry; ELISA, western-blot |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |